Lilly Invests In MiNA To Fund Protein-Upregulating RNA Programs

Eli Lilly And Co LLY is set to invest $15 million in its small activating RNA (saRNA) partner, MiNA Therapeutics.
The investment comes two months after Lilly agreed to pay $25 million upfront to work with MiNA on up to five targets.
MiNA will use the money to advance its internal pipeline of saRNA therapeutics, led by a drug designed to cut immunosuppression by raising levels of the C/EBP-⍺ master regulator of myeloid cell differentiation.
Price Action: LLY shares are up 0.05% at $234.07 during the market session on the last check Tuesday.

Momentum30.46

Growth99.77

Quality89.15

Value3.68

Short

Medium

Long